• Agrimol B protects against cisplatin-induced acute kidney injury by activating the Sirt1/Nrf2 signaling pathway, reducing oxidative stress and renal damage.
• Network pharmacology identified Sirt1 as a critical target of agrimol B, and experimental validation confirmed its role in mediating renoprotective effects.
• Agrimol B synergizes with cisplatin in antitumor activity, suggesting it may be a safe adjunct to chemotherapy without compromising efficacy.
• These findings highlight agrimol B as a promising therapeutic candidate for preventing cisplatin-induced nephrotoxicity in clinical settings.